65后王振滔交班80后刘大伟 康华生物新治理团队就位

Core Viewpoint - Sichuan vaccine leader Kanghua Biotech (300841.SZ) announced a board and executive adjustment, with Liu Dawei, a seasoned professional in the pharmaceutical industry born in the 1980s, appointed as chairman, while the original actual controller, "Wenzhou Shoe King" Wang Zhentao, moved to the position of vice chairman [2]. Group 1: Board and Executive Changes - The company completed the board member election during the first temporary shareholders' meeting on November 21, 2025, and approved the election of the chairman and vice chairman [5]. - The third board of Kanghua Biotech consists of 7 non-independent directors and 4 independent directors, with Liu Dawei as chairman and Wang Zhentao as vice chairman [6]. - Wu Wenian resigned as the financial head due to work adjustments but remains as vice president and board secretary; Fan Changyong was appointed as executive vice president, and Huang Hanmei was appointed as vice president and financial head [6]. Group 2: Company Performance - For the first three quarters of 2025, Kanghua Biotech reported revenue of 840 million yuan, a year-on-year decrease of 20.78%; net profit attributable to shareholders was 189 million yuan, down 53.41%; and net profit after deducting non-recurring items was 183 million yuan, a decline of 55.57% [6]. - Following the completion of the new board and executive team adjustments, market focus is shifting towards resource integration and development, but the core product revenue decline and a performance commitment of no less than 728 million yuan in net profit from 2025 to 2026 raise concerns about the company's potential turnaround [7].